| Ticker | CGM |
|---|---|
| ISIN | US2300311063 |
| Sector | Atención sanitaria |
| Mercado | NASDAQ |
Cullinan Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the developing of oncology and immuno-oncology therapies. Its pipeline includes CLN-978, CLN-619, Zipalertinib CLN-081/TAS6417, CLN-049, and CLN-617. The company was founded by Patrick A. Baeuerle on September 15, 2016 and is headquartered in Cambridge, MA.
Cullinan Oncology, Inc. opera en el sector Healthcare, industria Medical - Pharmaceuticals.